Skip to main content

Table 3 Comparison of CR rate among genotypes after 2 courses of Ara-C based chemotherapy

From: Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

Genotype Total (n) CR, n (%) Non-CR, n (%) P OR (95% CI) P a OR (95% CI)a
CMPK1 rs7543016
 CC 93 57 (61.3%) 36 (38.7%)   1.00 (reference)   1.00 (reference)
 GC 167 106 (63.5%) 61 (36.5%) 0.727 0.911 (0.540–1.537) 0.921 0.970 (0.531–1.772)
 GG 30 23 (76.7%) 7 (23.3%) 0.125 0.482 (0.188–1.238) 0.076 0.365 (0.120–1.111)
NME1 rs3760468
 AA 115 77 (67.0%) 38 (33.0%)   1.00 (reference)   1.00 (reference)
 AT 154 96 (62.3%) 58 (37.7%) 0.434 1.224 (0.737–2.033) 0.256 1.420 (0.775–2.597)
 TT 44 26 (59.1%) 18 (40.9%) 0.353 1.403 (0.686–2.869) 0.465 1.359 (0.597–3.096)
NME1 rs2302254
 CC 186 123 (66.1%) 63 (33.9%)   1.00 (reference)   1.00 (reference)
 CT 114 65 (57.0%) 49 (43.0%) 0.114 1.473 (0.912–2.375) 0.288 1.355 (0.775–2.370)
 TT 19 13 (68.4%) 6 (31.6%) 0.840 0.901 (0.327–2.481) 0.534 0.688 (0.212–2.232)
NME2 rs3744660
 GG 213 146 (68.5%) 67 (31.5%)   1.00 (reference)   1.00 (reference)
 AG 89 48 (53.9%) 41 (46.1%) 0.016 1.861 (1.121–3.091) 0.024 1.953 (1.092–3.484)
 AA 14 8 (57.1%) 6 (42.9%) 0.376 1.634 (0.545–4.897) 0.770 1.299 (0.361–4.673)
 AA+AG 103 56 (54.4%) 47 (45.6%) 0.014 1.829 (1.127–2.967) 0.030 1.852 (1.062–3.236)
SAMHD1 rs6102991
 AA 88 49 (55.7%) 39 (44.3%)   1.00 (reference)   1.00 (reference)
 GA 161 107 (66.5%) 54 (33.5%) 0.093 0.634 (0.372–1.080) 0.183 0.669 (0.370–1.209)
 GG 62 43 (69.4%) 19 (30.6%) 0.090 0.555 (0.280–1.101) 0.063 0.483 (0.224–1.038)
 AG+GG 223 150 (67.3%) 73 (32.7%) 0.055 0.611 (0.369–1.013) 0.086 0.611 (0.349–1.071)
SAMHD1 rs28372906
 TT 284 180 (63.4%) 104 (36.6%)   1.00 (reference)   1.00 (reference)
 CT 32 21 (65.6%) 11 (34.4%) 0.802 0.907 (0.420–1.955) 0.878 0.935 (0.394–2.217)
 CC 4 3 (75.0%) 1 (25.0%) 0.632 0.577 (0.059–5.618) 0.953 0.933 (0.091–9.524)
SAMHD1 rs6029941
 GG 88 50 (56.8%) 38 (43.2%)   1.00 (reference)   1.00 (reference)
 GA 161 107 (66.5%) 54 (33.5%) 0.132 0.664 (0.389–1.132) 0.339 0.739 (0.398–1.374)
 AA 65 42 (64.6%) 23 (35.4%) 0.330 0.721 (0.372–1.395) 0.370 0.706 (0.330–1.512)
E2F1 rs3213180
 GG 149 95 (63.8%) 54 (36.2%)   1.00 (reference)   1.00 (reference)
 GC 141 90 (63.8%) 51 (36.2%) 0.990 0.997 (0.617–1.610) 0.915 0.970 (0.552–1.704)
 CC 29 16 (55.2%) 13 (44.8%) 0.383 1.429 (0.639–3.195) 0.429 1.449 (0.578–3.636)
E2F1 rs3213150
 CC 111 67 (60.4%) 44 (39.6%)   1.00 (reference)   1.00 (reference)
 CT 159 110 (69.2%) 49 (30.8%) 0.133 0.678 (0.408–1.127) 0.105 0.616 (0.343–1.106)
 TT 46 23 (50.0%) 23 (50.0%) 0.232 1.523 (0.762–3.042) 0.128 1.835 (0.839–4.016)
 CC+CT 270 177 (65.6%) 93 (34.4%)   1.00 (reference)   1.00 (reference)
 TT 46 23 (50.0%) 23 (50.0%) 0.043 1.903 (1.014–3.574) 0.033 2.208 (1.065–4.567)
RRM1 rs183484
 GG 100 62 (62.0%) 38 (38.0%)   1.00 (reference)   1.00 (reference)
 GT 177 118 (66.7%) 59 (33.3%) 0.434 0.816 (0.490–1.359) 0.112 0.617 (0.340–1.119)
 TT 42 22 (52.4%) 20 (47.6%) 0.287 1.483 (0.716–3.071) 0.263 1.616 (0.697–3.731)
RRM1 rs2412344
 TT 89 56 (62.9%) 33 (37.1%)   1.00 (reference)   1.00 (reference)
 CT 183 119 (65.0%) 64 (35.0%) 0.734 0.913 (0.539–1.545) 0.510 0.817 (0.449–1.488)
 CC 48 28 (58.3%) 20 (41.7%) 0.599 1.212 (0.592–2.483) 0.967 1.018 (0.429–2.415)
RRM2 rs1130609
 TT 131 84 (64.1%) 47 (35.9%)   1.00 (reference)   1.00 (reference)
 GT 149 100 (67.1%) 49 (32.9%) 0.599 0.876 (0.534–1.436) 0.920 0.972 (0.557–1.697)
 GG 34 15 (44.1%) 19 (55.9%) 0.034 2.264 (1.053–4.867) 0.069 2.347 (0.935–5.882)
 TT+GT 280 184 (65.7%) 96 (34.3%)   1.00 (reference)   1.00 (reference)
 GG 34 15 (44.1%) 19 (55.9%) 0.014 2.428 (1.181–4.990) 0.044 2.398 (1.025–5.618)
  1. aAdjusted by age, risk stratification, WBC count, and serum LDH level